Mutant KRAS inhibitors enter the scene of precision therapeutics for pancreatic cancer. J Gastrointest Oncol 2024 Aug 31;15(4):1996-2001
Date
09/16/2024Pubmed ID
39279937Pubmed Central ID
PMC11399826DOI
10.21037/jgo-24-326Scopus ID
2-s2.0-85203321495 (requires institutional sign-in at Scopus site)Author List
Pollin G, Lomberk GA, Mathison AJ, Zimmermann MT, Urrutia RAuthors
Gwen Lomberk PhD Professor in the Surgery department at Medical College of WisconsinAngela Mathison PhD Assistant Professor in the Surgery department at Medical College of Wisconsin
Gareth Pollin PhD Postdoctoral Researcher 3 in the Surgery department at Medical College of Wisconsin
Michael T. Zimmermann PhD Director, Assistant Professor in the Data Science Institute department at Medical College of Wisconsin